Business
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
– Presentations to highlight significant opportunities targeting farnesyl transferase inhibition – SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kura
About this update from Kura Oncology, Inc.
[{"type":"text","content":"– Presentations to highlight significant opportunities targeting farnesyl transferase inhibition –\nSAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans from April 8-13, 2022. “We look forward to showcasing the four abstracts for tipifarnib, including a late-breaking presentation highlighting the opportunity for our next-generation farnesyl transferase inhibitor program,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “We are excited about this emerging opportunity, focused on delaying the onset of drug resistance and look forward to sharing more detailed information at AACR next month. In the meantime, we intend to perform initial clinical evaluation with tipifarnib in non-small cell lung cancer while in parallel advancing KO-2806, the lead development candidate in our next-generation farnesyl transferase inhibitor program, through IND-enabling studies.” Session titles and information for the four abstracts are listed below and are now available on the AACR online itinerary planner. Tipifarnib prevents emergence of resistance to osimertinib in EGFR-mutant NSCLC Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 1 / Chemistry Session Date and Time: Monday Apr 11, 2022; 1:30 PM - 5:00 PM CTLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 16 Abstract / Poster: LB080 / 5 A Phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (The KURRENT trial) Session Title: Phase I Trials in Progress 2Session Date and Time: Wednesday Apr 13, 2022; 9:00 AM - 12:30 PM CTLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 35Abstract / Poster: CT253 / 14 Tipifarnib potentiates the antitumor effects of PI3Ka blockade in HNSCC via convergent inhibition of mTOR activity Session Title: Experimental and Molecular Therapeutics - Mechanisms of Drug ...